PLSM:NASDAQPulsenmore Ltd. Analysis
Data as of 2026-04-24 - not real-time
$3.37
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Pulsenmore Ltd. (PLSM) trades at $3.37, well below its DCF‑derived fair value of roughly $44, indicating a deep discount. The 20‑day SMA sits just above the current price, while the 50‑day and 200‑day SMAs are higher, confirming a short‑term bearish bias. RSI at just under 40 points to near‑oversold conditions, suggesting a possible rebound. MACD shows a bullish signal as the line sits above the signal line, with a small positive histogram. Volume is trending upward, yet average daily volume remains modest, underscoring limited liquidity. Volatility over the past 30 days exceeds 70%, reflecting price swings.
The company reports zero revenue and negative margins, with a trailing EPS of –$0.82, highlighting ongoing profitability challenges. Nonetheless, free cash flow is positive, and the remote‑ultrasound market in Europe and Israel offers a growth runway. Beta is low (~0.16), indicating low sensitivity to broader market moves, while the Fear & Greed Index signals “Extreme Greed,” implying heightened speculative appetite. The support level at $3 aligns with the current price, but the nearest resistance near $3.93 could cap upside in the near term. Given the mix of deep valuation discount, technical signs of a bounce, and sector‑specific risks, investors should weigh upside potential against liquidity and regulatory uncertainties.
The company reports zero revenue and negative margins, with a trailing EPS of –$0.82, highlighting ongoing profitability challenges. Nonetheless, free cash flow is positive, and the remote‑ultrasound market in Europe and Israel offers a growth runway. Beta is low (~0.16), indicating low sensitivity to broader market moves, while the Fear & Greed Index signals “Extreme Greed,” implying heightened speculative appetite. The support level at $3 aligns with the current price, but the nearest resistance near $3.93 could cap upside in the near term. Given the mix of deep valuation discount, technical signs of a bounce, and sector‑specific risks, investors should weigh upside potential against liquidity and regulatory uncertainties.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering at immediate support around $3
- Bearish trend indicated by SMA hierarchy
- Rising volume but overall low liquidity
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Significant undervaluation versus DCF fair value
- Bullish MACD crossover suggesting momentum shift
- Growth opportunity in remote ultrasound diagnostics
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Long‑run market potential for tele‑ultrasound devices
- Low beta reducing systematic market risk
- Extreme Greed sentiment may fuel speculative upside
Key Metrics & Analysis
Financial Health
Revenue Growth578.30%
Profit Margin-39.61%
ROE-17.62%
ROA-6.24%
Debt/Equity1.88
Free Cash Flow$7.7M
Industry P/E25.4
Technical Analysis
TrendBearish
RSI40.0
Support$3.00
Resistance$3.93
MA 20$3.53
MA 50$4.12
MA 200$4.59
MACDBullish
VolumeIncreasing
Fear & Greed Index88.02
Valuation
Fair Value$43.60
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.16
Volatility72.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.